Lumos Pharma (FRA:4NX1) Accounts Payable & Accrued Expense : €2.18 Mil (As of Mar. 2024)

View and export this data going back to 2011. Start your Free Trial

What is Lumos Pharma Accounts Payable & Accrued Expense?

Lumos Pharma's quarterly accounts payable & accrued expense increased from Sep. 2023 (€2.98 Mil) to Dec. 2023 (€3.00 Mil) but then declined from Dec. 2023 (€3.00 Mil) to Mar. 2024 (€2.18 Mil).

Lumos Pharma's annual accounts payable & accrued expense increased from Dec. 2021 (€1.74 Mil) to Dec. 2022 (€2.59 Mil) and increased from Dec. 2022 (€2.59 Mil) to Dec. 2023 (€3.00 Mil).

Lumos Pharma Accounts Payable & Accrued Expense Historical Data

The historical data trend for Lumos Pharma's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lumos Pharma Accounts Payable & Accrued Expense Chart

Lumos Pharma Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Accounts Payable & Accrued Expense

Get a 7-Day Free Trial

0.97

5.05

1.74

2.59

3.00

Lumos Pharma Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Accounts Payable & Accrued Expense	Get a 7-Day Free Trial															2.96	3.63	2.98	3.00	2.18

Lumos Pharma Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

Lumos Pharma (FRA:4NX1) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lumos Pharma Inc (FRA:4NX1) » Definitions » Accounts Payable & Accrued Expense

Comparable Companies

Traded in Other Exchanges

LUMO:USA

Address

4200 Marathon Boulevard, Suite 200, Austin, TX, USA, 78756

Website

https://www.lumos-pharma.com

Lumos Pharma Inc is a biopharmaceutical company that develops treatments for cancer and rare diseases. It carries out both clinical-stage and preclinical research on a range of molecules that help the immune system fight off cancer cells. The treatments are available orally and can be used in conjunction with other cancer therapies. The company also researches an Ebola vaccine. Lumos contracts with manufacturing organizations to make their treatments, engages in partnerships with pharmaceutical companies, and operates primarily in the United States.

Lumos Pharma (FRA:4NX1) Headlines

No Headlines